Published online before print December 27, 2005, doi: 10.1161/CIRCULATIONAHA.105.591537
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:108-117.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
Cyclooxygenase-1 Deficiency in Bone Marrow Cells Increases Early Atherosclerosis in Apolipoprotein E– and Low-Density Lipoprotein Receptor–Null Mice
From the Department of Medicine (V.R.B., L.D., S.F., M.F.L.), Pediatrics (J.R., S.K.D.), Molecular Physiology & Biophysics (J.D.M.), Nephrology (M.D.B.), Pathology (S.F.), and Pharmacology (M.F.L.) of Vanderbilt University Medical Center, Nashville, Tenn.
Correspondence to Vladimir Babaev, Sergio Fazio, or MacRae F. Linton, Department of Cardiovascular Medicine, Vanderbilt University School of Medicine, 312 PRB, 2220 Pierce Ave, Nashville, TN 37232-6300. E-mail vladimir.babaev{at}vanderbilt.edu, sergio.fazio@vanderbilt.edu, or macrae.linton@vanderbilt.edu
Received June 11, 2005; de novo received September 28, 2005; accepted October 21, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Cyclooxygenase-1 (COX-1) has been implicated in the pathogenesis of atherothrombosis and is expressed by the major cell types of atherosclerotic lesions. COX-1–mediated platelet thromboxane (TX) production has been proposed to promote both early atherosclerosis and thrombosis. Here, we examined the impact of COX-1 deficiency in bone marrow–derived cells on early atherogenesis in the mouse.
Methods and Results— LDL receptor (LDLR)–/– and apolipoprotein E (apoE)–/– recipient mice were lethally irradiated and transplanted with COX-1–/– bone marrow. Mice reconstituted with COX-1–/– marrow had nearly complete (99.7%) loss of platelet TXA2 and significantly suppressed levels of macrophage and urinary TXA2 metabolites. Serum lipid levels and lipoprotein distributions did not differ between recipients reconstituted with COX-1+/+ and COX-1–/– marrow. Surprisingly, the extent of atherosclerotic lesions in both LDLR–/– and apoE–/– mice reconstituted with COX-1–/– marrow was increased significantly compared with control mice transplanted with COX-1+/+ marrow. Peritoneal macrophages isolated from LDLR–/– mice reconstituted with COX-1–/– marrow had increased lipopolysaccharide-induced levels of COX-2 mRNA and protein expression. Fetal liver cell transplantation studies revealed a 30% increase in atherosclerosis in COX-1–/–
LDLR–/–mice compared with COX-1+/+LDLR–/–mice, whereas the extent of atherosclerosis was unchanged in COX-1–/–/COX-2–/–LDLR–/–mice.
Conclusions— COX-1 deficiency in bone marrow–derived cells worsens early atherosclerosis in apoE–/– and LDLR–/– mice despite virtual elimination of platelet TX production. These data demonstrate that platelet TX production does not aggravate early atherosclerotic lesion formation and that upregulation of COX-2 expression in COX-1–/– macrophages is proatherogenic.
Key Words: platelets • macrophages • cyclooxygenase • prostaglandins • thromboxane
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Eicosanoids are lipid-derived autacoids implicated in a large number of pathological processes, including inflammation and atherosclerosis. Prostaglandins are generated by cyclooxygenase (COX) through conversion of arachidonic acid to prostaglandin H, which is further catalyzed by the distinct synthases to 5 major bioactive prostaglandins (eg, PGE2, PGI2, PGF2
, PGD2, and TXA2). COX exists as 2 isoforms, COX-1 and COX-2, encoded by 2 separate genes.1,2 COX-1 is constitutively expressed in every major cell type involved in the pathogenesis of atherothrombosis, including vascular cells, macrophages, and platelets. In contrast, COX-2 is induced rapidly at sites of inflammation and is expressed in atherosclerotic lesions.3,4 TXA2 is a potent stimulus of platelet aggregation, vasoconstriction, and vascular proliferation.5 Platelet TXA2 production, a COX-1–mediated process, is viewed as promoting atherothrombosis. In contrast, prostacyclin (PGI2) is a potent vasodilator and platelet inhibitor and is viewed as being antiatherothrombotic.5 The balance between TXA2 and PGI2 has been proposed to be an important determinant in the pathogenesis of atherosclerosis and thrombosis resulting in cardiovascular events.
Clinical Perspective p 117
Nonselective inhibition of COX has been reported to reduce atherosclerosis both in cholesterol-fed rabbits6 and in murine models of atherosclerosis.7,8 COX-1 has been proposed to promote the development of atherosclerosis in LDL receptor (LDLR)–/– mice.8 On the basis of studies with a COX-1 inhibitor, Belton et al9 have implicated COX-1–mediated platelet thromboxane (TX) A2 generation in promoting the early stages of atherosclerotic lesion formation. In humans, a low dose of aspirin (100 mg/d) significantly decreases the relative risk and total frequency of cardiovascular events.10 The beneficial effects of aspirin in reducing cardiovascular events have been largely attributed to inhibition of COX-1–mediated platelet TX production.11,12
Genetic deficiency in the TXA2 receptor suppresses vascular proliferation and platelet activation in an arterial injury–induced model of neointimal hyperplasia in mice13 and inhibits atherosclerosis in apolipoprotein E (apoE)–/– mice.14 Similarly, the administration of the TXA2 antagonist S-18886 suppresses the development of atherosclerotic lesions in apoE–/– mice.15,16 However, aspirin alone was more efficient in TX inhibition, with only slight effects on the development of atherosclerosis, compared with S-18886, which suggests that a mechanism independent of platelet-derived TX is responsible for suppression of the development of atherosclerosis.15 Because TX is abundantly expressed by platelets, macrophages, endothelial cells, and smooth muscle cells, the impact of TX production by different vascular cells on atherogenesis may vary depending on the stage of atherosclerotic lesion formation.
To examine the impact of COX-1 gene expression by bone marrow–derived cells on the development of atherosclerosis, LDLR–/– and apoE–/– mice were lethally irradiated and transplanted with COX-1–/– or COX-1+/+ marrow. In recipient mice reconstituted with COX-1–/– bone marrow–derived cells, platelet TXA2 production was virtually eliminated, and production of urinary and macrophage TXA2 metabolites was significantly reduced. Surprisingly, mice reconstituted with COX-1–/– bone marrow had increased atherosclerotic lesions in the absence of significant differences in serum lipids. These data demonstrate that COX-1–mediated platelet TXA2 production is not a major driving force in early atherosclerotic lesion formation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Procedures
COX-1 null mice17 were crossed onto the C57BL/6 background (sixth backcross) and mated with apoE–/– mice on the C57BL/6 background (from Jackson Laboratories Inc, Bar Harbor, Me) to obtain COX-1–/–, apoE–/– bone marrow donors. All recipient LDLR–/– and apoE–/– mice were on the C57BL/6 background and maintained in microisolator cages on a rodent chow diet containing 4.5% fat (PMI No. 5010). Animal care and experimental procedures were performed according to the regulations of Vanderbilt University’s Animal Care Committee.
Bone Marrow Transplantation
Recipient LDLR–/– and apoE–/– mice were lethally irradiated (9 Gy) from a cesium gamma source and transplanted with 5x106 bone marrow cells as described previously.18
Serum Lipids and Lipoprotein Distribution Analysis
The serum total cholesterol and triglyceride levels were determined on samples obtained from mice fasted for 4 hours as described previously.19 Fast performance liquid chromatography was performed on an HPLC system model 600 (Waters) with a Superose 6 column (Pharmacia).
Platelet and Urinary Prostaglandin Metabolites
To measure TXA2 metabolite levels, blood samples, peritoneal macrophages, or freshly isolated bone marrow cells were incubated in DMEM media containing 0.5% BSA, 5 µmol/L A23187 Ca2+ ionophore (Calbiochem), and 2 µmol/L arachidonic acid at 37°C for 30 or 120 minutes, respectively. Twenty-four-hour urine samples were purified by solid-phase extraction. Prostaglandins and prostaglandin metabolites were measured by gas chromatography/mass spectrometry with SCIEX API III+ triple quadrupole (Applied Biosystems) as described previously.20
Analysis of Aortic Lesions
Aortas were flushed through the left ventricle, and the entire aorta was dissected for en face analysis as described previously.21 Cryosections of the proximal aorta were analyzed according to Paigen et al22 with an Imaging System KS 300 (Kontron Electronik GmbH.).
Flow Cytometric Analysis
Blood cells were blocked with anti-Fc
RII/III antibodies, incubated with anti-mouse CD3, CD4, and CD8 antibodies labeled with allophycocyanin, fluorescein isothiocyanate, and phycoerythrin, respectively (BD PharMingen, La Jolla, Calif), and 7AAD (7-amino-actinomycin D). Cells were then fixed and analyzed by 4-color flow cytometry with the Becton Dickinson fluorescent-activated cell sorter (Becton Dickinson).
Immunocytochemistry
Serial 5-µm cryosections of the proximal aorta were incubated with monoclonal rat antibodies to mouse glycoprotein IIb, CD41 (BD PharMingen, San Diego, Calif) specific for platelets,23 or macrophages (MOMA-2; Accurate Chemical & Scientific Corp, Westbury, NY). The sections were treated with goat biotinylated antibodies to rat IgG (PharMingen), incubated with avidin-biotin complex labeled with alkaline phosphatase (Vector Laboratories), and visualized with Fast Red TR/Naphthol AS-NX substrate (Sigma). A nonimmune rat serum was used as a negative control.
Western Blotting
Peritoneal macrophages were stimulated (50 ng/mL lipopolysaccharide [LPS]) for 5 hours and lysed in the presence of protease inhibitor (Roche Diagnostics). Extracted proteins were analyzed with rabbit antibodies to murine COX-2 (Cayman Chemical, Ann Arbor, Mich), ß-actin (Abcam, Inc, Cambridge, Mass), and horseradish peroxidase–conjugated goat anti-rabbit antibodies (Upstate Cell Signaling, Lake Placid, NY).
RNA Isolation and Real-Time Polymerase Chain Reaction
Total RNA was isolated from peritoneal macrophages with Trizol reagent (Life Technologies, Inc) and purified with an RNA Easy kit (Qiagen). Relative quantification of the target mRNA was performed with the ABI Prism 7700 Sequence Detection System (Applied Biosystems) and normalized with 18S ribosomal RNA as an endogenous control. Primers and probes for 18S and COX-2 were obtained from Applied Biosystems.
Statistical Analysis
Statistical differences in mean serum lipids and aortic lesion areas between the groups were determined by Student t test, the Mann-Whitney rank sum test, and a 1-way ANOVA tests with SigmaStat version 2 software (SPSS Inc).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Generation of Chimeric Mice With COX-1–/– Bone Marrow–Derived Cells
To evaluate the impact of COX-1 expression by bone marrow cells on atherosclerosis, 7-week-old male LDLR–/– mice were lethally irradiated and transplanted with male COX-1+/+ (n=14, control group) or COX-1–/– (n=17; experimental group) marrow. After 4 weeks on a normal chow diet, they were fed a Western diet for 8 weeks. In a separate set of experiments, 8-week-old female apoE–/– mice were lethally irradiated, transplanted with COX-1+/+/apoE–/– (n=13) or COX-1–/–/apoE–/– (n=13) bone marrow cells, and fed a normal chow diet for 9 weeks. Eight weeks after transplantation, peritoneal macrophages isolated from recipient mice reconstituted with COX-1–/– marrow did not express COX-1, as demonstrated by real-time polymerase chain reaction analysis (data not shown), verifying their change in genotype.
Bone Marrow and Platelet and Urinary Eicosanoids
The impact of COX-1 deficiency on secretion of eicosanoids by freshly harvested bone marrow stimulated with the A23187 Ca2+ ionophore (5 µmol/L) was examined in vitro. Compared with bone marrow cells from wild-type mice, bone marrow cells from COX-1–/– mice had significantly lower levels of all types of prostanoids examined, including PGF2 (0.90±0.11 versus 0.30±0.02 ng/mL; P<0.001), 2,3-dinor 6-keto PGF1 (0.027±0.003 versus 0.008±0.003 ng/mL; P<0.01), PGE2 (2.78±0.21 versus 1.19± 0.10 ng/mL; P<0.001), TXB2 (2.27±0.23 versus 0.13±0.01 ng/mL; P<0.001), and PGD2 (5.36±0.29 versus 2.49±0.21 ng/mL; P<0.001). Next, we evaluated the impact of elimination of COX-1 expression in bone marrow–derived cells on Ca2+ ionophore–stimulated platelet TXA2 production. After stimulation with 5 µmol/L A23187, production of platelet TXA2 metabolite TXB2 was virtually eliminated (99.7% reduction) in COX-1–/–LDLR–/– mice compared with COX-1+/+LDLR–/– mice (0.3±0.1 versus 139.4±15.8 ng/mL; P<0.001). The reduction in platelet TXB2 production was similar to the 99.5% reduction in platelet TXB2 production seen in COX-1–/– mice versus wild-type littermates (0.8±0.3 versus 149.9±39.5 ng/mL; P<0.02). Furthermore, in the COX-1–/–LDLR–/– mice, the urinary excretions of both of the TX metabolites 11 dehydro- and 2,3-dinor-TXB2, were reduced to a similar extent, 79% and 74%, respectively (Figure 1A). In contrast, levels of the urinary prostacyclin metabolite 2,3-dinor-6-keto-PGF1, PGE-M, and isoprostane were not altered compared with the levels of these metabolites in mice reconstituted with wild-type marrow (Figure 1B). Thus, COX-1 expression in bone marrow–derived cells is responsible for &75% of systemic TX production.
|
Serum Lipids and Lipoprotein Distribution
There were no significant differences in serum lipid levels between LDLR–/– recipients reconstituted with COX-1–/– and COX-1+/+ marrow on either the chow or the Western diets (Table 1). Similarly, serum lipid levels in COX-1–/–/apoE–/–apoE–/– mice did not differ from control COX-1+/+/ apoE–/–apoE–/– mice with the exception that their triglycerides were higher at week 11 of the experiment (Table 2). Analysis of the serum samples by size exclusion chromatography revealed an accumulation of cholesterol in the VLDL, LDL, and IDL fractions in both LDLR–/– and apoE–/– recipients, with no differences between control and experimental groups in either experiment (Figures 2A and 2B). These data indicate that COX-1 deficiency in marrow-derived cells does not affect plasma lipids in either LDLR–/– or apoE–/– recipient mice.
|
|
|
) bone marrow (A) and apoE–/– recipients reconstituted with COX-1+/+/apoE–/– (•) or COX-1–/–/apoE–/– (
Quantification of Atherosclerotic Lesions
The extent of atherosclerotic lesions in the proximal aortas of LDLR–/– recipients reconstituted with COX-1–/– marrow cells was significantly greater than for COX-1+/+LDLR–/– (124 196±27 631 versus 61 566±1610 µm2; P<0.03, Figure 3A). There was a statistically nonsignificant trend for increased atherosclerosis in the distal aortas of COX-1–/– LDLR–/– mice compared with control mice (Figure 3B). Similarly, COX-1–/–/apoE–/–apoE–/– mice had larger atherosclerotic lesions in their proximal aortas (39 463±3090 versus 28 352±2791 µm2; P<0.02) and their distal aortas (0.20±0.01% versus 0.18±0.01%; P<0.05) analyzed en face (Figures 4C and 4D) than control COX-1+/+/apoE–/– apoE–/– mice. Thus, COX-1 deficiency in bone marrow–derived cells accelerates development of atherosclerotic lesions.
|
|
Glycoprotein IIb Staining in Atherosclerotic Lesions
All groups of recipient mice developed moderate fatty streak lesions, consisting predominantly of macrophage-derived foam cells stained by the anti-macrophage antibody MOMA-2 (Figures 4A and 4B). Serial sections from the proximal aorta of apoE–/– recipients were stained with the antibody to platelet glycoprotein IIb, CD41. Interestingly, the atherosclerotic lesions of the COX-1+/+/apoE–/– apoE–/– control mice appeared to contain substantially more platelets, as indicated by CD41 staining, than COX-1–/–/apoE–/–apoE–/– mice (Figures 4C and 4D). Quantitative image analysis of these sections demonstrated that the COX-1+/+/apoE–/–apoE–/– mice had a 2-fold greater percentage of their lesion area staining for CD41 than apoE–/– mice reconstituted with COX-1–/– marrow (Figure 4F).
CD4/CD8 T-Cell Phenotype
Because COX-1 has been reported to impact T-cell development,24 we studied whether the impact of COX-1 deficiency affected the proportion of CD4 and CD8 peripheral blood T cell subsets analyzed by 4-color staining flow cytometry. In COX-1 null control mice, there was a significant decrease in CD8 and an increase in CD4 T-cells compared with wild-type mice (38.6±1.1% and 57.4±1.5% versus 44.0±1.0% and 50.5±1.5%; P=0.016 and P=0.023, respectively). In contrast, LDLR–/– recipients reconstituted with COX-1–/– marrow had no significant differences in the number or the proportion of CD8+ and CD4+ cells compared with mice transplanted with COX-1+/+ marrow (41.9±3.4% and 54.3±3.4% versus 41±1.1% and 55.5±0.9%; P=0.82 and P=0.75, respectively).
Macrophage Prostaglandins and COX-2 Expression
To analyze how COX-1 deficiency affects macrophage prostaglandin production, peritoneal macrophages were isolated from LDLR–/– recipients reconstituted with COX-1+/+ and COX-1–/– marrow. In response to A23187 5 µmol/L, peritoneal macrophages derived from COX-1–/– LDLR–/– mice maintained similar levels of PGF2, PGE2, and PGD2 production, whereas synthesis of PGI2 and TXA2 metabolites was reduced by 62% and 16%, respectively, compared with control COX-1+/+LDLR–/– macrophages (Figure 5).
|
Previous studies have indicated that COX-2 expression may be increased in COX-1–deficient cells.25 Therefore, we examined the expression of COX-2 in COX-1–/– macrophages at baseline and in response to LPS. Peritoneal macrophages were isolated from LDLR–/– recipients after 8 weeks of the Western diet. The macrophages isolated from COX-1–/–LDLR–/– mice had increased basal and LPS-stimulated levels of COX-2 expression as analyzed by real-time quantitative polymerase chain reaction analysis (Figure 6A) compared with macrophages isolated from COX-1+/+LDLR–/–mice. To verify these findings, peritoneal macrophages were isolated from COX-1–/– and wild-type mice and incubated with LPS. Again, COX-1–/– macrophages responded to LPS activation with significantly higher (195%) levels of COX-2 gene activation than wild-type macrophages (Figure 6B). Liver X receptor- (LXR) agonists have previously been reported to mediate reciprocal regulation of genes involved in inflammation and cholesterol homeostasis in macrophages.26 Therefore, we examined the ability of an LXR agonist, TO-901317, to downregulate COX-2 expression in COX-1–deficient macrophages. The LXR agonist significantly reduced COX-2 gene expression by 45% and 40% in COX-1–/– and wild-type macrophages, respectively (Figure 6B). In addition, COX-2 protein expression levels were analyzed in LPS-stimulated peritoneal macrophages from COX-1–/– and wild-type mice. Macrophages from COX-1–/– mice had significantly increased (18%) levels of COX-2 protein expression compared with macrophages from wild-type mice (Figures 6C and 6D).
|
Generation of LDLR–/– Mice Null for Expression of Both COX-1 and COX-2 Genes in Bone Marrow–Derived Cells
We have previously reported that elimination of COX-2 expression in bone marrow–derived cells reduces atherosclerosis in LDLR–/– and C57BL/6 mice, which supports a proatherogenic role for macrophage COX-2 in early atherogenesis.27 To further examine the hypothesis that compensatory upregulation of COX-2 in macrophages may have contributed to the increased atherosclerosis in COX-1+/+LDLR–/–mice, we generated LDLR–/– mice with bone marrow–derived cells null for both COX-1 and COX-2. Because the double knockout of both COX-1 and COX-2 genes is lethal in mice soon after birth,28 we used the approach of fetal liver cell (FLC) transplantation.29 Briefly, 8-week-old female LDLR–/– mice were lethally irradiated and transplanted with female COX-1+/+ (n=20), COX-1–/– (n=13), or COX-1–/–/COX-2–/– (n=13) FLCs. After 6 weeks on a chow diet, the recipient mice were fed the Western diet for 8 weeks. There were no differences in plasma lipid levels between these groups of mice (Table 3); however, mice transplanted with COX-1–/– FLCs had bigger (30%) atherosclerotic lesions in the distal aortas analyzed en face (0.26±0.01) than control mice reconstituted with COX-1+/+ (0.20±0.02; P<0.05) or mice with COX-1–/–/COX-2–/– (0.20±0.02) FLCs (Figure 7). Thus, deletion of both COX-1–/–/COX-2–/– in bone marrow–derived cells eliminated the increase in atherosclerosis seen in COX-1+/+LDLR–/–mice, which supports the hypothesis that the observed increase in macrophage COX-2 expression contributed to the increase in atherosclerosis in the COX-1–/–LDLR–/–mice.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
COX-1 is expressed by all cell types involved in the pathogenesis of atherothrombosis, including endothelial cells, vascular smooth muscle cells, macrophages, and platelets. COX-1 has been reported to promote atherosclerosis in murine models, and COX-1–mediated platelet TXA2 production has been proposed to be responsible for the proatherogenic effects of COX-1 in early lesion formation. However, the relative impact of COX-1 expression by vascular cells and cells of hematopoietic origin on atherogenesis remains unclear. Therefore, we examined the impact of COX-1 expression by bone marrow–derived cells on early atherosclerotic lesion formation by generating both LDLR–/– and apoE–/– mice chimeric for COX-1 expression by bone marrow–derived cells. Platelet production of TXA2 was virtually eliminated and the urinary TXA2 metabolites were dramatically reduced in the mice reconstituted with COX-1–/– bone marrow. Surprisingly, both LDLR–/– and apoE–/– recipient mice reconstituted with COX-1–/– bone marrow cells had significantly increased atherosclerotic lesion area compared with control mice transplanted with COX-1+/+ marrow, in the absence of significant differences in serum lipids or lipoprotein profiles. These results demonstrate that COX-1–mediated platelet TX production is not a significant driving force in the development of early atherosclerotic lesion formation in LDLR–/– or apoE–/– mice. Furthermore, the net effect of the loss of COX-1–mediated eicosanoid production from bone marrow–derived cells on early lesion formation is proatherogenic. Hence, any possible beneficial effects of the loss of platelet TX in early atherogenesis may be outweighed either by the loss of production of antiatherogenic COX-1–mediated eicosanoids from bone marrow–derived cells, production of proatherogenic COX-1–mediated eicosanoids by vascular cells, or a proatherogenic effect that is mediated by compensatory upregulation of COX-2 expression in macrophages. We provide strong support for a proatherogenic role of COX-2 expression by demonstrating that elimination of both COX-1 and COX-2 in bone marrow–derived cells of LDLR-deficient mice eliminates the increase in atherosclerosis attributable to deficiency of COX-1 in bone marrow–derived cells (Figure 7).
In the present studies, elimination of COX-1 expression in bone marrow–derived cells in apoE–/– and LDLR–/– mice resulted in virtually complete elimination of platelet TX. This proves that platelet TXA2 production is entirely COX-1–mediated and that the recipient mice were completely reconstituted with donor bone marrow. Urinary TX excretion was reduced by 74% to 79% in the mice reconstituted with COX-1–/– bone marrow (Figure 1), which indicates that platelets and bone marrow–derived cells are responsible for the vast majority of urinary TXB2. Given the rather small impact of COX-1 deficiency on macrophage TXB2 production (Figure 5), it is likely that platelets are responsible for the production of the majority of systemic TX production, as reflected by urinary TXB2. In contrast, urinary F2 isoprostanes, the prostacyclin metabolite 2,3-dinor 6-keto PGF1, and PGE-M did not differ between control and experimental mice (Figure 1), which indicates that COX-1 expression in bone marrow–derived cells is not a significant contributor to the systemic production of F2 isoprostanes or prostacyclin. Furthermore, COX-1 expression in bone marrow–derived cells does not significantly affect plasma lipid or lipoprotein metabolism (Figure 2; Tables 1 and 2
).
TX is widely held to promote atherothrombosis, because it promotes activation and aggregation of platelets and is a potent vasoconstrictor.5 Treatment of mice with a TX receptor antagonist15 and genetic elimination of the receptor14 significantly diminished atherogenesis. In contrast, prostacyclin inhibits platelet aggregation and is a potent vasodilator. The balance between prostacyclin and TX has been proposed to be an important determinant of both the development of atherosclerosis and thrombosis resulting in cardiovascular events.5,27 The beneficial effect of aspirin in reducing cardiovascular events is largely attributed to its ability to reduce platelet aggregation by inhibiting COX-1–mediated platelet TX production.11,12 Recently, the increased risk of cardiovascular events seen with COX-2 inhibitors has been attributed to a tilting of this balance, which results from reductions in PGI2 without an impact on platelet TX production.30 However, this paradigm has been challenged recently31 on the basis of studies by McAdam et al32 demonstrating COX-2–mediated production of PGI2 and nonplatelet-mediated TXA2 in smokers. The results of the present study do not address the issue of whether the balance between PGI2 and TX is a critical determinant of thrombosis and cardiovascular events. However, given our finding of increased early atherogenesis in the face of a dramatic reduction in urinary TX with no change in urinary PGI2, the present results indicate that the balance between TX and PGI2 is not a critical determinant of early atherosclerotic lesion formation.
COX-1 has been proposed to promote the development of atherosclerosis in LDLR–/– mice on the basis of the observation that the nonselective inhibitor indomethacin significantly reduced atherosclerosis, whereas the selective COX-2 inhibitor nimesulide produced a nonsignificant trend for a reduction in lesion area.8 Belton et al9 have implicated COX-1 in promoting the early stages of lesion formation, because treatment of apoE–/– mice fed a 1% cholesterol diet with the selective COX-1 inhibitor SC-560 for 8 weeks dramatically reduced atherosclerotic lesion formation, whereas SC560 did not induce regression or inhibit progression of established lesions. Although SC-560 did not prevent platelet adhesion in these studies, Belton et al9 suggested that the most likely explanation for the reduction in atherosclerosis was inhibition of platelet activation due to inhibition of COX-1–meditated platelet TXA2 generation. Consistent with the results of Belton et al,9 we have found that treatment of male LDLR–/– mice fed a Western diet with the COX-1 inhibitor SC-560 caused dramatic reductions both in urinary TX and in the extent of atherosclerosis compared with vehicle-treated mice (M.F.L., unpublished results). However, the present results demonstrate that platelet TX production is not a dominant driver of early atherosclerotic lesion formation, because elimination of COX-1 in bone marrow–derived cells results in increased atherosclerosis in 2 murine models (Figure 3) despite complete elimination of platelet TXA2 production. Therefore, the ability of SC-560 to reduce early atherosclerotic lesion formation is likely to be independent of its effect on inhibition of platelet TXA2 production. Interestingly, Cayatte et al15 have proposed that TXA2 receptor (TP) agonists other than TX, such as F2 isoprostanes and HETE, are responsible for TP-mediated promotion of atherosclerosis, on the basis of a finding that a TX receptor antagonist reduced atherosclerosis in apoE-deficient mice, whereas aspirin, which completely inhibited platelet TX production, did not affect the extent of atherosclerosis. Given that levels of F2 isoprostanes were not influenced by the elimination of COX-1 in bone marrow–derived cells (Figure 1), the possibility that a difference in this alternative TP agonist may have contributed to TP-mediated promotion of atherosclerosis in the present studies seems unlikely.
Our results demonstrating increased atherosclerosis in apoE–/– and LDLR–/– mice reconstituted with COX-1–/– bone marrow suggest that COX-1 expression by bone marrow cells is on balance antiatherogenic. Given the key role of monocyte recruitment and macrophage foam cell formation in early lesion formation, we examined the impact of COX-1 deficiency on peritoneal macrophage eicosanoid production after stimulation with a calcium ionophore. Interestingly, COX-1–/– macrophage production of PGI2 was reduced dramatically (62%), whereas TXB2 production was only slightly reduced (16%) and the levels of PGF2, PGE2, and PGD2 were unchanged compared with COX-1+/+ macrophages (Figure 5). PGI2 exhibits protective properties by inhibiting platelet aggregation and smooth muscle cell proliferation.13 Macrophage PGI2 reduces cholesterol uptake and foam cell formation but does not interfere with cholesterol export.33 In addition, PGI2 analogues dose-dependently inhibited production of inflammatory cytokines (tumor necrosis factor-, interleukin-1ß, and granulocyte-macrophage colony–stimulating factor) by human alveolar macrophages.34,35 Thus, the suppression of PGI2 production in COX-1–/– macrophages in the present studies may accelerate the development of atherosclerosis by promoting foam cell formation and the production of inflammatory cytokines. COX-1 deficiency has been reported to impact T-cell development24; however, we did not see a change in CD4/CD8 phenotype in T cells from mice reconstituted with COX-1–/– compared with COX-1+/+ bone marrow. Therefore, an impact of COX-1 expression on atherosclerosis mediated by T cells seems unlikely. A significant contribution of donor-derived COX-1–/– endothelial cells or smooth muscle cells to the development of atherosclerosis is unlikely in the present studies, because we have previously found that the contribution of bone marrow–derived endothelial cells and smooth muscle cells to atherosclerotic lesions is minimal (<2%) under similar conditions of early lesion development.36
Compensatory upregulation of the alternate COX isoform has been reported in macrophages isolated from COX-1– and COX-2– deficient mice.25 COX-2 compensation also occurs in the absence of COX-1 in a uterine preparation for implantation.37 In the present studies, peritoneal macrophages isolated from mice reconstituted with COX-1–/– marrow expressed significantly higher levels of basal and LPS-mediated COX-2. We have previously reported results of pharmacological and genetic studies that support a proatherogenic role for macrophage COX-2 expression in early atherosclerotic lesion formation.7,38 Hence, a compensatory increase in COX-2 expression in COX-1–/– macrophages may have contributed to the increase in atherosclerosis. Recent reports demonstrated that activation of the LXR pathway inhibits LPS- and cytokine-induced macrophage expression of a number of inflammatory genes, including COX-2.26 To test whether this LXR pathway for regulation of COX-2 expression was operative in COX-1 null cells, we incubated macrophages with LPS alone or with the LXR agonist TO-901317. COX-1–/– macrophages responded with a significantly higher activation of COX-2 gene, but the LXR agonist efficiently suppressed this upregulated COX-2 gene expression, which demonstrates that this LXR-mediated regulatory pathway is intact in COX-1 null cells (Figure 6B). To examine the hypothesis that COX-2 expression by COX-1 null macrophages contributed to the increased atherosclerosis in COX-1+/+ LDLR–/–mice, we used an FLC transplantation approach to generate mice with COX-1–/–/COX-2–/– bone marrow–derived cells. Interestingly, the 30% increase in atherosclerosis seen in LDLR–/– mice reconstituted with COX-1–/– FLCs was not seen in the LDLR–/– mice transplanted with COX-1–/–/COX-2–/– FLCs (Figure 7), which provides strong support for the hypothesis that the observed upregulation of COX-2 in COX-1–/– macrophages contributed significantly to the observed increase in atherosclerosis.
In summary, elimination of the COX-1 gene expression from bone marrow–derived cells significantly accelerates early atherosclerotic lesion formation in both LDLR–/– and apoE–/– recipient mice, despite virtually complete elimination of platelet TX. Furthermore, we provide evidence for compensatory upregulation of COX-2 in macrophages, as well as evidence that COX-2 expression contributes significantly to the increased atherosclerosis in mice reconstituted with COX-1 null bone marrow–derived cells. These results challenge current paradigms suggesting that COX-1–mediated platelet TX production and the balance of TX and PGI2 are critical determinants of atherosclerotic lesion formation.
|
Acknowledgments |
|---|
We thank Youmin Zhang for excellent technical expertise and Drs Garret FitzGerald and John Lawson (both from the University of Pennsylvania) for the urinary metabolites 2,3-dinor-TXB2 measurement. This work was supported by National Institutes of Health grants HL53989 and HL65405 (Dr Linton); HL57986, DK59637 (Lipid, Lipoprotein and Atherosclerosis Core of the Vanderbilt Mouse Metabolic Phenotype Centers; Dr Fazio); and HD12304, HD 33094 and DA 06668 (Dr Dey). Dr Babaev is supported by an American Heart Association grant (0160160B). Disclosures None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. DuBois R, Abramson S, Crofford L, Gupta RA, Simon L, Van De Putte L, Lipsky P. Cyclooxygenase in biology and disease. FASEB J. 1998; 12: 1063–1073.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38: 97–120.[CrossRef][Medline] [Order article via Infotrieve]
3. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999; 19: 646–655.
4. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999; 155: 1281–1291.
5. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003; 2: 879–890.[CrossRef][Medline] [Order article via Infotrieve]
6. Bailey JM, Butler J. Anti-inflammatory drugs in experimental atherosclerosis, I: relative potencies for inhibiting plaque formation. Atherosclerosis. 1973; 17: 515–522.[CrossRef][Medline] [Order article via Infotrieve]
7. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002; 105: 1816–1823.
8. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001; 98: 3358–3363.
9. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation. 2003; 108: 3017–3023.
10. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003; 163: 2006–2010.
11. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997; 96: 2751–2753.
12. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003; 3: 107–112.[CrossRef][Medline] [Order article via Infotrieve]
13. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296: 539–541.
14. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004; 114: 784–794.[CrossRef][Medline] [Order article via Infotrieve]
15. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000; 20: 1724–1728.
16. Egan KM, Wang M, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005; 111: 334–342.
17. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995; 83: 483–492.[CrossRef][Medline] [Order article via Infotrieve]
18. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation. Science. 1995; 267: 1034–1037.
19. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB, Linton MF. Increased atherosclerosis in C57BL/6 mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A. 1997; 94: 4647–4652.
20. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem. 2000; 275: 13427–13430.
21. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem. 2000; 275: 26293–26299.
22. Paigen B, Holmes P, Mitchell D, Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, females, and testosterone-treated female mice from strains C57BL/6, BALB/c and C3H. Atherosclerosis. 1987; 68: 215–221.
23. Nieswandt B, Echtenacher B, Wachs FP, Schroder J, Gessner JE, Schmidt RE, Grau GE, Mannel DN. Acute systemic reaction and lung alterations induced by an antiplatelet integrin GP IIb/IIIa antibody in mice. Blood. 1999; 94: 684–693.
24. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999; 103: 1469–1477.[Medline] [Order article via Infotrieve]
25. Zhang J, Goorha S, Raghow R, Ballou LR. The tissue-specific, compensatory expression of cyclooxygenase-1 and -2 in transgenic mice. Prostaglandins Other Lipid Mediat. 2002; 67: 121–135.[CrossRef][Medline] [Order article via Infotrieve]
26. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003; 9: 213–219.[CrossRef][Medline] [Order article via Infotrieve]
27. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem. 2004; 11: 1243–1252.[Medline] [Order article via Infotrieve]
28. Reese J, Paria B, Brown N, Zhao X, Morrow J, Dey S. Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci U S A. 2000; 97: 9759–9764.
29. Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest. 1999; 103: 1697–1705.[Medline] [Order article via Infotrieve]
30. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351: 1709–1711.
31. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation. 2005; 112: 941–945.
32. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation. 2005; 112: 1024–1029.
33. Senna SM, Moraes RB, Bravo MF, Oliveira RR, Miotto GC, Vidor AC, Bello-Klein A, Irigoyen MC, Bello AA, Curi R, Homem de Bittencourt PI Jr. Effects of prostaglandins and nitric oxide on rat macrophage lipid metabolism in culture: implications for arterial wall-leukocyte interplay in atherosclerosis. Biochem Mol Biol Int. 1998; 46: 1007–1018.[Medline] [Order article via Infotrieve]
34. Nishimura T, Yamamoto T, Ueda Y, Yamada K, Hara Y. Stable prostaglandin I1 analog SM-10906 modulates productions of tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in mouse macrophages. Biol Pharm Bull. 2000; 23: 708–711.[Medline] [Order article via Infotrieve]
35. Raychaudhuri B, Malur A, Bonfield TL, Abraham S, Schilz RJ, Farver CF, Kavuru MS, Arroliga AC, Thomassen MJ. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J Biol Chem. 2002; 277: 33344–33348.
36. Huebner SB, Babaev VR, Zhang Y, Fazio S, Linton MF. Bone marrow stem cells are a source of smooth muscle and endothelial cells in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2003; 23: 84a. Abstract.
37. Reese J, Brown N, Paria BC, Morrow J, Dey SK. COX-2 compensation in the uterus of COX-1 deficient mice during the pre-implantation period. Mol Cell Endocrinol. 1999; 150: 23–31.[CrossRef][Medline] [Order article via Infotrieve]
38. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005; 39: 443–452.[CrossRef][Medline] [Order article via Infotrieve]
 |
|
 |
|
  T. Cyrus, Y. Yao, T. Ding, J. M. Dogne, and D. Pratico Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice Blood, April 15, 2007; 109(8): 3291 - 3296. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||